Works matching AU Park, Yeon Hee

Results: 186
    1
    2

    Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

    Published in:
    Oncologist, 2025, v. 30, n. 5, p. 1, doi. 10.1093/oncolo/oyaf048
    By:
    • Ueno, Naoto T;
    • Cottone, Francesco;
    • Dunton, Kyle;
    • Jacot, William;
    • Yamashita, Toshinari;
    • Sohn, Joohyuk;
    • Tokunaga, Eriko;
    • Prat, Aleix;
    • Tsurutani, Junji;
    • Park, Yeon Hee;
    • Rugo, Hope S;
    • Xu, Binghe;
    • Cardoso, Fatima;
    • Mitri, Zahi;
    • Mahtani, Reshma;
    • Aguilar, Cecilia Orbegoso;
    • Xiao, Feng;
    • Harbeck, Nadia;
    • Cameron, David A;
    • Modi, Shanu
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.

    Published in:
    Breast Cancer Research, 2025, v. 27, n. 1, p. 1, doi. 10.1186/s13058-024-01946-y
    By:
    • Dent, Rebecca;
    • Cortés, Javier;
    • Park, Yeon Hee;
    • Muñoz-Couselo, Eva;
    • Kim, Sung-Bae;
    • Sohn, Joohyuk;
    • Im, Seock-Ah;
    • Holgado, Esther;
    • Foukakis, Theodoros;
    • Kümmel, Sherko;
    • Yearley, Jennifer;
    • Wang, Anran;
    • Nebozhyn, Michael;
    • Huang, Lingkang;
    • Cristescu, Razvan;
    • Jelinic, Petar;
    • Karantza, Vassiliki;
    • Schmid, Peter
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 10, p. 1, doi. 10.1007/s00262-024-03782-7
    By:
    • Park, Changhee;
    • Suh, Koung Jin;
    • Kim, Se Hyun;
    • Lee, Kyung-Hun;
    • Im, Seock-Ah;
    • Kim, Min Hwan;
    • Sohn, Joohyuk;
    • Jeong, Jae Ho;
    • Jung, Kyung Hae;
    • Lee, Kyoung Eun;
    • Park, Yeon Hee;
    • Kim, Hee-Jun;
    • Cho, Eun Kyung;
    • Choi, In Sil;
    • Noh, Seung-Jae;
    • Shin, Inkyung;
    • Cho, Dae-Yeon;
    • Kim, Jee Hyun
    Publication type:
    Article
    22
    23
    24
    25
    26
    27
    28

    c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.

    Published in:
    Breast Cancer Research, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13058-024-01768-y
    By:
    • Park, Jieun;
    • Chang, Eun Sol;
    • Kim, Ji-Yeon;
    • Chelakkot, Chaithanya;
    • Sung, Minjung;
    • Song, Ji-Young;
    • Jung, Kyungsoo;
    • Lee, Ji Hye;
    • Choi, Jun Young;
    • Kim, Na Young;
    • Lee, Hyegyeong;
    • Kang, Mi-Ran;
    • Kwon, Mi Jeong;
    • Shin, Young Kee;
    • Park, Yeon Hee;
    • Choi, Yoon-La
    Publication type:
    Article
    29
    30
    31
    32

    Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers.

    Published in:
    BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03638-y
    By:
    • Lee, Ji Yoon;
    • Lee, Ji Won;
    • Chung, Min Sung;
    • Choi, Jong Gwon;
    • Sim, Sung Hoon;
    • Kim, Hyo Jeong;
    • Kim, Jeong Eun;
    • Lee, Kyoung Eun;
    • Park, Yeon Hee;
    • Kang, Myoung Joo;
    • Ahn, Mi Sun;
    • Chae, Yee Soo;
    • Park, Ji Hyun;
    • Kim, Jee Hyun;
    • Kim, Gun Min;
    • Byun, Jae Ho;
    • Park, Keon Uk;
    • Kim, Ju Won;
    • Jung, Seung Pil;
    • Lee, Jung Hyun
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.

    Published in:
    JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 10, p. 1654, doi. 10.1093/jnci/djae129
    By:
    • Dent, Rebecca;
    • Cortés, Javier;
    • Pusztai, Lajos;
    • McArthur, Heather;
    • Kümmel, Sherko;
    • Bergh, Jonas;
    • Denkert, Carsten;
    • Park, Yeon Hee;
    • Hui, Rina;
    • Harbeck, Nadia;
    • Takahashi, Masato;
    • Untch, Michael;
    • Fasching, Peter A;
    • Cardoso, Fatima;
    • Haiderali, Amin;
    • Jia, Liyi;
    • Nguyen, Allison Martin;
    • Pan, Wilbur;
    • O'Shaughnessy, Joyce;
    • Schmid, Peter
    Publication type:
    Article
    44
    45
    46
    47
    48
    49

    Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer.

    Published in:
    Cancer Science, 2024, v. 115, n. 9, p. 3079, doi. 10.1111/cas.16234
    By:
    • Iwata, Hiroji;
    • Xu, Binghe;
    • Kim, Sung‐Bae;
    • Chung, Wei‐Pang;
    • Park, Yeon Hee;
    • Kim, Min Hwan;
    • Tseng, Ling‐Ming;
    • Chung, Chi‐Feng;
    • Huang, Chiun‐Sheng;
    • Kim, Jee Hyun;
    • Chiu, Joanne Wing Yan;
    • Yamashita, Toshinari;
    • Li, Wei;
    • Egorov, Anton;
    • Nishijima, Soichiro;
    • Nakatani, Shunsuke;
    • Nishiyama, Yuji;
    • Sugihara, Masahiro;
    • Cortés, Javier;
    • Im, Seock‐Ah
    Publication type:
    Article
    50